Meeting Report: Hazard Assessment for Nanoparticles—Report from an Interdisciplinary Workshop by Balbus, John M. et al.
1654 VOLUME 115 | NUMBER 11 | November 2007 • Environmental Health Perspectives
Research
Close to 400 manufacturer-identified nan-
otechnology-based consumer products are now
on the market (Woodrow Wilson International
Center for Scholars 2007). Using increasingly
sophisticated levels of control over the assem-
bly of atoms and molecules to form substances
and devices, nanotech companies are exploit-
ing the size-dependent properties of nanostruc-
tured materials for applications ranging from
cosmetics to fuel cells (Colvin 2003). Yet our
understanding of the potential toxicity of
nanoparticles remains rudimentary (Colvin
2003; Oberdörster et al. 2005b). To determine
whether the unique chemical and physical
properties of new nanoparticles result in spe-
ciﬁc toxicologic properties, the nanotechnol-
ogy community needs new ways of evaluating
hazard and ultimately assessing risk (Nel et al.
2006). These new strategies must also con-
sider the complexities inherent to studies of
chemical mixtures.
This workshop’s assessment of the novel
aspects of nanotoxicology built on knowledge
gained from prior workshops. In 2004,
scientists from many different areas of
research came together in Gainesville,
Florida, to discuss the emerging ﬁeld of nan-
otoxicology (Bucher et al. 2004). They
described the challenges facing toxicologists
in rigorously characterizing the new materials
and in understanding how nanostructures
might differentially influence toxicity. This
theme was further elaborated in a seminal
article by Oberdörster et al. (2005a), which
provides a general framework for evaluating
the toxicity of engineered nanoparticles.
More detailed questions regarding exactly
how to evaluate the potential health impact of
engineered nanoparticles remain. This report
captures some of the critical information that
is still needed to understand the human health
impact of engineered nanoparticles and deﬁnes
mechanisms to begin to acquire this informa-
tion. Building on the insight from those previ-
ous meetings and published articles—that the
structure of nanoparticles brings many new
challenges to toxicological evaluation—work-
shop participants were asked to identify both
factors that make nanoparticles different and
information speciﬁc to these differences that is
needed to assess nanoparticle hazards. The
group was further charged with making rec-
ommendations on how to gather and use that
additional information to evaluate health haz-
ards associated with these scale-speciﬁc proper-
ties. Because of the short duration of this
workshop, the scope was limited to considera-
tion of toxic properties of nanoparticles. A full
evaluation of human health risks will require
development of sufﬁcient techniques for assess-
ing exposure to nanoparticles in addition to
consideration of toxicity.
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In this report we present the ﬁndings from a nanotoxicology workshop held 6–7 April 2006 at the
Woodrow Wilson International Center for Scholars in Washington, DC. Over 2 days, 26 scientists
from government, academia, industry, and nonproﬁt organizations addressed two speciﬁc questions:
what information is needed to understand the human health impact of engineered nanoparticles and
how is this information best obtained? To assess hazards of nanoparticles in the near-term, most par-
ticipants noted the need to use existing in vivo toxicologic tests because of their greater familiarity
and interpretability. For all types of toxicology tests, the best measures of nanoparticle dose need to
be determined. Most participants agreed that a standard set of nanoparticles should be validated by
laboratories worldwide and made available for benchmarking tests of other newly created nanoparti-
cles. The group concluded that a battery of tests should be developed to uncover particularly haz-
ardous properties. Given the large number of diverse materials, most participants favored a tiered
approach. Over the long term, research aimed at developing a mechanistic understanding of the
numerous characteristics that inﬂuence nanoparticle toxicity was deemed essential. Predicting the
potential toxicity of emerging nanoparticles will require hypothesis-driven research that elucidates
how physicochemical parameters inﬂuence toxic effects on biological systems. Research needs should
be determined in the context of the current availability of testing methods for nanoscale particles.
Finally, the group identiﬁed general policy and strategic opportunities to accelerate the development
and implementation of testing protocols and ensure that the information generated is translated
effectively for all stakeholders. Key words: nanomaterials, nanoparticle, nanotechnology, nanotoxicol-
ogy, particle toxicology. Environ Health Perspect 115:1664–1659 (2007). doi:10.1289/ehp.10327
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opened the workshop with a presentation that
explored ways of thinking about and evaluat-
ing the potential hazards of nanoparticles. She
emphasized focus on the nanoscale interac-
tions that take place in the normal functioning
of biological systems in order to understand
the positive and negative effects that engi-
neered nanoparticles could have on humans.
For example, because the immune system
functions through nanoscale intercellular
communications, Lynch et al. (2006) hypoth-
esized that engineered nanoparticles can dis-
rupt these processes with deleterious end
results. Specifically, they considered unique
interactions between native proteins and the
highly curved surfaces of nanoparticles, specu-
lating that the protein shape could be modi-
fied after binding. This deformation could
expose amino acid residues that are normally
buried in the core of the protein, and the
immune system would then recognize these
newly exposed residues as “cryptic epitopes”
and mount an unwanted immune response.
A 2005 study by Zhao et al. (2005) pre-
dicted that DNA repair, another vital biologi-
cal system that operates at the nanoscale, is
also susceptible to modiﬁcation by nanoparti-
cles. Specifically, this study found through
computer modeling that the association in
water between C60 and DNA is stronger than
the association between two C60 molecules.
Therefore, when DNA is damaged, fullerenes
can occupy the damaged site, possibly imped-
ing the self-repairing processes of the double-
strand DNA and thus negatively impacting
the structure, stability, and biological func-
tions of DNA molecules.
These unique interactions between
nanoparticles and biological systems afford
great promise for medicinal applications, but
the unintended consequences could be harm-
ful. We know, for instance, that natural and
unintentionally produced ultraﬁne particulate
matter, which is in the same size range as engi-
neered nanoparticles, can carry a broad range
of compounds, including polycyclic aromatic
hydrocarbons, endotoxin, metals, and other
toxic chemicals. These complexes can then
damage biological systems (Penn et al. 2005;
Schwarze et al. 2006). Gutierrez-Castillo et al.
(2006) found that particulate matter with
chemicals adsorbed to the surface can damage
DNA. These examples suggest that the myriad
possible interactions between nanoparticles and
harmful environmental chemicals may lead to
unique exposures and health risks.
Conventional knowledge about exposure
assessment, fate and transport, and current
computer models is not necessarily applicable
to nanoparticles. But alternative methods such
as toxicogenomic technologies, lower-order
animal and in vitro testing, and ultimately the
development of structure activity models could
prove useful, providing more rapid testing than
traditional animal toxicology tests and allowing
for explicit experimental design based on
mechanism. The development of alternative
methods is an ambitious but necessary goal if
the large and growing numbers of nanoparti-
cles are to be adequately assessed for toxicity.
Silbergeld ended her presentation with a
charge for the group: to frame its dialogue
both to inform the industry on how to look
before leaping into the production of new
nanoparticles and to provide guidance for
those who have already taken that leap.
Objectives 
Participants were asked to address two speciﬁc
questions:
Question 1: In light of the special physi-
cal, chemical, and biological properties of
engineered nanoparticles, what information is
needed to assess the human health hazards of
nanoparticles that are currently in or likely
soon to reach commercial production?
Question 2: How can information needed
to assess the human health hazards of
nanoparticles that are currently in or likely
soon to reach commercial production be
obtained most expeditiously and efﬁciently?
The workshop employed alternating ple-
nary and multidisciplinary breakout sessions to
consider these questions in detail. Consensus of
viewpoints was noted but not required for each
of the points considered. Where viewpoints
differed has been captured in the discussion.
Results
Critical information needs for nanoparticle
toxicity. After developing separate lists of criti-
cal information needs in the breakout groups,
the participants produced the following con-
sensus priority list: a) extensive physico-
chemical characterization; b) capacity for
macromolecular perturbation; c) potential for
unintended carriage of toxic molecules;
d) translocation; e) agglomeration state;
f ) and chemical composition.
A brief description of each type of infor-
mation is given below, followed by a discus-
sion of the adequacy of traditional toxicology
testing to detect potentially novel forms of
toxicity from nanoparticles.
Extensive physicochemical characteriza-
tion. Participants agreed that engineered
nanoparticles must be appropriately character-
ized if the results of toxicity tests are to be inter-
preted and compared. Characterization would
include particle size, size distribution, shape,
surface area (some proposed specifying bioavail-
able surface area), redox potential and proper-
ties, purity/identity of contaminants, and
catalytic activity, in addition to generation of
reactive oxygen species. Materials must be char-
acterized not just initially but repeatedly in
order to reﬂect their physicochemical state in
relevant environmental media and their poten-
tial transformation at the portal of entry (e.g.,
the lung, skin, and gastrointestinal tract) and at
the target organ. In addition, characterization of
the material should be carried out for all phases
of the product lifecycle during which exposure
or release may be anticipated. Standardized pro-
tocols for nanoparticle characterization will be
essential to assure consistency across laborato-
ries. Agglomeration state was considered a key
physical characteristic of engineered nanoparti-
cles and is discussed separately below.
Macromolecular perturbation. Participants
agreed on the need to determine the degree to
which particular nanoparticles, because of their
size and physicochemical properties, could
engage in unique interactions with biologically
critical macromolecules, including DNA,
cytoskeletal elements, collagen, and membrane
structures. Participants summarized the evi-
dence assembled to date for such interactions
between natural and engineered nanoparticles,
including buckyballs with DNA (modeled),
carbon nanotubes with cellular nanotubes
(hypothetical), and protein adsorption and
modiﬁcation of self-recognition—the so-called
cryptic epitopes—discussed above.
Carrier role. Nanoparticles are currently
the subject of intense pharmacologic research
because of their capacity to carry and deliver
drugs to specific targets (Chavanpatil et al.
2006). This intrinsic property raises important
questions regarding the potential for nanopar-
ticles to carry toxic chemicals that may be pre-
sent in the environment. Penn et al. (2005)
recently described the ability of combustion-
generated ultraﬁne particulate matter to carry
toxic chemicals such as polycyclic aromatic
hydrocarbons. The association of endotoxin,
which can trigger an immune response that
complicates the interpretation of toxic response
in toxicological tests, is also a concern.
Participants agreed on the need to determine
the potential for nanoparticles to become carri-
ers for toxic substances, for example, by trans-
porting them within the hollow structures
designed for functional payloads (as in nan-
otubes, dendrimers, and buckyballs) or
adsorbed to their surfaces.
Translocation. Participants agreed on the
need to determine the likelihood that
nanoparticles would not be detected by
macrophages in the lungs and consequently
translocate through alveolar cell membranes
into the general circulation. These processes
may be critical to determining the ultimate
toxicity of nanoparticles. Detailed mechanistic
insight into the relationship between nanopar-
ticle composition and physicochemical prop-
erties and membrane translocation may reveal
ways to “engineer out” the capacity for wide-
spread distribution and subsequent toxicity
through modification of surface coatings or
other aspects of nanoparticles.
Hazard assessment for nanoparticles
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agglomerate rapidly at high concentrations.
Agglomeration state has a profound impact
on particle size and structure. Individual
nanoparticles when agglomerated may create
particles that are no longer in the nanoscale
size range. Whether those agglomerated parti-
cles retain toxic properties of the individual
nanoparticles or are capable of subsequently
de-agglomerating is a critical question.
Agglomeration state as measured in air or
water may change inside the body through
interactions with biological fluids and pro-
teins and change further still within different
tissue/cellular/subcellular compartments that
deﬁne different optimal afﬁnities for the par-
ticles and biological macromolecules.
Chemical composition. Some participants
pointed out that bulk chemical composition
may be a secondary contributor to nanoparticle
functionality because interactions with poorly
soluble nanoparticles are conﬁned to the sur-
faces of the material. This means that structural
parameters such as surface charge, shape, area,
and reactivity are the primary contributors and
more immediate mediators of nanoparticle
function and toxicity. Particle solubility is
another important parameter with respect to
the importance of chemical composition.
Composition is clearly of greater importance
when particles dissolve over time with the body
than when they are insoluble and excreted or
stored without any appreciable dissolution. In
discussions, it was noted that bulk chemical
composition may correlate well with biological
activity for some materials and should be mea-
sured as a matter of course in studies.
Adequacy of traditional toxicology tests.
For the purposes of this workshop, the term
“traditional” refers to those toxicology tests
with well-established protocols that have been
used in regulatory and risk assessment settings
for many years. These are typically but not
necessarily whole animal tests employing
histopathology for confirmation of toxicity.
The term “apical” refers to the fact that the end
points assessed in these tests may be the ulti-
mate manifestation of a variety of different
pathways of toxicity. Although participants
generally agreed that traditional whole animal
toxicology tests would likely show end points
of toxicity even if the mechanisms were new,
some disagreed as to how adequate those apical
tests were for detecting all relevant types of tox-
icity and noted that scientists need to be open
to detecting novel end points. Some partici-
pants suggested that the use of molecular tech-
nologies, including toxicogenomics and
proteomics, may be more efﬁcient at identify-
ing novel mechanisms of toxicity.
Participants noted that a number of critical
capabilities are currently lacking for nanoparti-
cles, including: a) methods to adequately char-
acterize them, especially when present in
biological media; b) a validated set of in vitro
assays with which to develop a proﬁle of mech-
anistic information relevant to nanoparticles
(with the possible exception of assays for gener-
ation of reactive oxygen species); and c) sufﬁ-
cient experience and data to be able to predict
the toxicity of nanoparticles on the basis of
their physicochemical characteristics or mecha-
nistic assays. In the face of these shortcomings,
most of the group agreed on the urgent need
both for traditional toxicologic testing on
presently available materials, particularly those
most likely to have widespread exposures, and
for mechanistic assays, to begin assembling the
database that will ultimately enable structure–
function predictions and acquisition of biologi-
cal insight into mechanisms of pathogenesis.
Many in the group urged caution, however, to
ensure that ﬁndings of mechanistic assays are
not overinterpreted. These themes are elabo-
rated to some degree in the next section.
An additional critical need is the develop-
ment of absorption–distribution–metabolism
and excretion (ADME) methods and studies.
The general framework for ADME should be
the same for nanoparticles, but the analytical
challenges of detecting nanoparticles, as well as
their by-products if they are transformed or
metabolized, are signiﬁcant. Some nanoparti-
cles (e.g., quantum dots, magnetic nanocrys-
tals) have special properties that make their
real-time in vivo imaging straightforward.
However, such imaging is not quantitative
and must be conﬁrmed by tissue analysis tests.
Additionally, heavy reliance on imaging may
not capture the dissolution or transformation
of particles or their coatings. Nanoparticles
that do not have intrinsic ﬂuorescence or other
properties that aid visualization present a
greater challenge to accurate determination of
their ADME characteristics.
Strategies for developing needed informa-
tion on nanoparticle toxicity. In reconciling the
urgent need for better understanding of
nanoparticle toxicity with the fact that many of
the methods for obtaining that understanding
are in need of development, the participants
distinguished two lines of research for nanotox-
icology, as noted previously. The first is to
develop data on materials to which workers
and the general population are already being
exposed, and the second is to create new, better
methods for accurate and efficient testing of
hazards and exposure potential, which will cre-
ate new knowledge to guide the future devel-
opment of nanoparticles. In addition to
research priorities, participants emphasized the
need to provide appropriate worker protection
in the absence of data on potential hazards.
The group identified a number of com-
plementary strategies for gathering the infor-
mation needed to assess nanoparticle toxicity,
including:
• promoting cross-disciplinary communication;
• developing a set of “representative nanopar-
ticles” for benchmarking; and
• developing agreement on a tiered testing
program.
In addition, participants developed a
chart depicting the current availability of test
methods for various types of information
needed to assess nanoparticle toxicity in order
to facilitate research prioritization and
methods development.
Cross-disciplinary communication.
Sufficient information on the risks of nano-
technology will come only through close
collaboration among researchers across disci-
plines. Because in-depth understanding of
nanoparticle toxicology requires elucidation of
the relationship between physicochemical para-
meters and mechanisms of toxicity, greater
communication is needed between physical
chemists skilled in characterization of materials
and toxicologists and biologists able to discern
mechanisms for toxicity. Participants therefore
developed a framework for describing the
interrelationships among material chemists,
cell biologists, developmental biologists, phar-
macokineticists, and toxicologists.
Nanoparticle design processes (Figure 1,
left side) typically seek to correlate physical
structure with material properties. This facili-
tates optimization of technologies and creates
a rich framework for scientific study.
Nanotoxicology (Figure 1, right side) operates
in an analogous context but with a focus on
biological and toxicologic properties. Within
this framework, information about nanoparticle
structure is an important input for biological
scientists. Because particle structure (e.g., size,
surface coating) in a biological setting can be
quite different from that measured in a materi-
als laboratory, an ongoing dialogue between
material scientists and biological scientists
(dotted two-way arrow) will greatly facilitate
the design of safer nanoparticles. In addition,
characterization of the physicochemical
Balbus et al.
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Figure 1. The parallel relationship between mater-
ial design and material testing (nanotechnology
and nanotoxicology).
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Nanotoxicologyproperties should inform the toxicologic
testing process.
Participants also emphasized the need for
developing a “community of practice” for
nanotoxicology. Elements of this could
include the development of standard materials
discussed below, as well as workshops and
internet listservers to facilitate communication
among groups. The development of a stan-
dard format for reporting results of nanotoxi-
cology assays, analogous to effort to
standardized formatting for toxicogenomics
was also suggested [e.g., MIAME (Minimum
Information About a Microarray Experiment)
2007 and MIAPE (Minimum Information
About a Proteomics Experiment) 2007].
Emphasis for this standardized format would
be the novel wealth of information on physic-
ochemical information that will accompany
nanotoxicology studies. Last, to promote a
broader understanding and shared interpreta-
tion of the dynamic scientiﬁc literature of nan-
otoxicology, some participants recommended
a standing body modeled on the Cochrane
Collaboration, which publishes the Cochrane
reviews of evidence for clinical practice. This
standing body, for maximum effectiveness and
credibility, would comprise representatives of
the various stakeholder groups, including
academia, industry, government, labor, and
nongovernmental organizations.
Developing a set of representative
nanoparticles for benchmarking. One area of
convergent discussion was the need to proceed
with full characterization and toxicity testing
for a representative set of nanoparticles. The
group could not agree on a simple method of
selecting a limited set from such a broad and
diverse class of materials; even within one class
there is currently no way to determine which
material is the most representative. The partic-
ipants’ compromise proposal was to initiate
data generation on a group of substances that
come from different categories of nanoparti-
cles; ideally, these materials would be closely
related to those currently used in commerce.
The data to be generated would include full
physicochemical characterization, an array of
in vitro mechanistic tests, and full traditional
toxicologic test batteries. Short-term toxico-
logic testing of nanoparticles (e.g., instillation
or aspiration studies with several months of
follow-up) was also deemed valuable to facili-
tate crude benchmarking against well-charac-
terized conventional materials on which these
tests have already been performed.
The choice of materials should reﬂect the
priorities of both scientists and regulators,
and should be defined within the context of
commercial use. Exploratory research, for
example, would be best served by using highly
pure and monodisperse nanoparticles,
whereas the commercially relevant materials
of immediate interest to regulators may be
more heterogeneous and ill-deﬁned. In addi-
tion, testing of these materials should be per-
formed in a manner that reflects the likely
routes of exposure based on expected use and
lifecycle characteristics of those materials. The
group concluded that the selection process
will require great care and deliberation
beyond the scope of this workshop.
Two further concepts related to represen-
tative materials emerged. First, participants
agreed that in addition to complete characteri-
zation and testing of a small number of mate-
rials, it would be useful to run a larger number
of materials through some of the same in vitro
and/or shorter in vivo assays to begin interpo-
lating results based on structure or other
physicochemical characteristics.
Second, the subset of representative mate-
rials being developed and tested should be cre-
ated in sufﬁcient quantities to be provided to
research laboratories as reference material.
Given the difficulty of manufacturing
nanoparticles and the dynamic nature of the
industry, relying on one company to provide a
reference material over a period of years was
deemed inadvisable. Rather, a small network
or consortium should be assembled to produce
each reference material to ensure continuity
should a business fail or stop production. An
essential function of this network would be to
establish tests that would ensure that the refer-
ence materials were of high quality, and most
critically, that they had physicochemical char-
acteristics that were constant over time.
Tiered testing program. An initial con-
ceptual model for a tiered testing system is
presented in Figure 2. Further work is needed
to reach consensus on the structure and trig-
gers for such a tiered system. At present, there
is insufﬁcient experience with in vitro mecha-
nistic studies and other high throughput
screening techniques to be able to employ
them as initial screens for nanoparticles in
place of standard toxicologic tests. Therefore,
at present, nanoparticles of concern would
need to be considered for tests in the second
tier for thorough hazard screening. As greater
structure–function and mechanistic under-
standing develops for nanoparticles, a tiered
program such as this should help achieve
more efﬁcient hazard screening.
Availability of test methods for determin-
ing properties of nanoparticles. To aid in the
prioritization of research and test methods
development, participants proposed using a
rating scheme for the availability of test meth-
ods to determine the different types of infor-
mation relevant to nanoparticle toxicity
(Figure 3). A red/yellow/green color coding
system was suggested to illustrate the maturity
of the available tests. Red indicates there is no
agreed upon test method and that the develop-
ment of one would be a high-priority research
need; yellow indicates that test methods are
available, but there is no consensus on the
proper method; and green indicates that there
are tests with sufﬁciently common usage that
they can be considered for standardization
within 12–18 months. Green does not indicate
that these tests have been validated for regula-
tory purposes but rather that they are well
established for nanoparticles. This table was
developed by the participants on the basis of
consideration of three types of nanoparticles:
dendrimers, metal oxides, and carbon nan-
otubes. It reﬂects the best judgment of partici-
pants at the time of the meeting and is not
intended to necessarily apply to other types of
nanoparticles.
Figure 3A addresses information needed for
the characterization of physical and chemical
properties. Because the physical and chemical
properties of nanoparticles can vary depending
on whether they are tested as prepared or
within biological settings, the availability was
considered separately for these different settings.
Similarly, Figure 3B considers methods for
assessing translocation and ADME properties
in acellular, cellular (in vitro) and in vivo sys-
tems, whereas Figure 3C considers methods for
assessing special chemistry of nanoparticles both
in vivo and ex vivo.
In addition to considering the availability
of methods to assess specific properties of
nanoparticles, the participants noted that
methods of addressing traditional challenges
of whole animal toxicology tests may be espe-
cially troublesome for nanoparticles because of
Hazard assessment for nanoparticles
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Figure 2. Proposal for a tiered human health hazard
assessment program—a decision algorithm for
deciding which tier of testing is needed but was
not produced during this workshop.
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Tier 2the potential for novel mechanisms of toxicity.
These challenges include extrapolating
between species, including from laboratory
animals to man, assessing interindividual vari-
ability, and using in vitro assays to predict
in vivo toxicity. Discussing these issues in the
same context as the availability of testing
methods, participants noted that there are no
currently available speciﬁc or novel approaches
to resolving these challenges for nanoparticles.
Conclusions
Consistent with previous workshops, most of
the attendees concluded that at present, stan-
dard toxicologic tests are needed to assess the
risks of nanoparticles. Even though opinion
diverged on the most relevant tests, there was
consensus that, for adequate risk management,
nanoparticles nearing commercialization
should be subjected to a battery of short-term
in vitro and in vivo tests to determine broadly
the effects on key target organs and possible
molecular mechanisms of toxicity. The partici-
pants recommended eventually developing a
tiered testing approach in which primarily
in vitro screening tests would be designed to
uncover particular properties that would then
trigger more extensive evaluation. To facilitate
the appropriate interpretation of testing
results, standard reference materials, testing
methods, and reporting formats must be
developed for nanoparticles and shared among
groups worldwide.
The group further concluded that nano-
toxicology research should lead to general prin-
ciples, ideally predictive in nature, that
associate material properties with toxicity.
Research toward this goal would require exten-
sive collaboration between nanotechnologists
and toxicologists. Because many of the toxico-
logic tests needed for hazard identiﬁcation are
not well developed for nanoparticles or still
require validation, priority should be given to
research into tier 1 tests that are not yet easily
translated to nanoparticles. And because many
of the challenges for nanotoxicology are shared
by other specializations within the ﬁeld of toxi-
cology, further research is needed into the
validity of key tests, particularly the predictive
nature of in vitro for in vivo results.
Finally, all participants recognized the
importance of effective communication for
sharing of information on nanotoxicology and
informing science-based public and corporate
decision making. One recurrent theme was
the opportunity for misunderstanding because
of the differences in meaning and perspectives
among the various disciplines engaged in the
workshop. As this report illustrates, the techni-
cal barriers to advancing the science are also
signiﬁcant, and research of the proposed mag-
nitude can only happen with sustained fund-
ing from government and industry. To ensure
the most effective use of limited research
funds, all stakeholders must participate in
designing a strong research strategy based on
sound science and the consensus of experts
worldwide. All parties should also recognize
the critical role of public communication in
this arena; more than in any other area of nan-
otechnology, this topic requires strong, neu-
tral, and well-funded public outreach
programs that equip consumers and policy-
makers to engage in the issues at the highest
possible technical level.
Recommendations
Although some of the following recommen-
dations mirror or build upon previously pub-
lished recommendations (e.g., Maynard et al.
2006; Oberdörster et al. 2005a), they are also
the product of a broader multidisciplinary
and multistakeholder dialogue:
a) Establish a coordinated federal research
agenda in the United States for understanding
the human health impacts of nanoparticles—
a “Master Research Plan”—with signiﬁcantly
increased funding from all relevant sectors.
b) Convene specialized workshops and
fund research to advance testing capabilities,
including: 
• novel characterization methods for use in
biological settings;
• in vitro assay selection and validation for
nanoparticle tiered testing;
• use of physicochemical information to pre-
dict and understand biological mechanisms
and toxicity;
• study of ADME issues and their connection
to nanomedical research; such information
would include where particles distribute
over time, tissues and organs in which they
may accumulate or deposit, how the body
transforms the materials, and when and how
they are excreted; and
• integrative models that provide a complete
picture of a nanoparticle’s effects and serve
as the basis for predictive correlations for
the impacts of novel nanoparticles.
c) Develop a multidisciplinary community
of practice and information-sharing forum for
researchers and all interested stakeholders.
d) Develop and make available a set of ref-
erence nanoparticles for research laboratories
to use as controls/benchmarks in their studies.
e) Work toward quantitative risk assess-
ment by selecting a set of three to ﬁve speciﬁc
nanoparticles for full physicochemical charac-
terization, and in vitro and in vivo testing.
Additional work on exposure assessment will
also be necessary. This could be accomplished
within one country such as the United States
or within the context of an intergovernmental
group, such as the Organization for Economic
Cooperation and Development (OECD).
f ) Develop a standardized format for
reporting the results of nanoparticle toxico-
logical studies, focusing on physicochemical
characterization. Engage major scientiﬁc jour-
nals and government research agencies to
require such particle characterization for pub-
lication and grant reporting.
g) Require that a minimal set of physico-
chemical information be provided for all
commercial products.
h) Create a third-party body, similar to
the Cochrane model but comprised of stake-
holders from all groups, to review and provide
authoritative interpretations of research in
nanotoxicology.
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